On August 31, AKESO fell 3.15% in regular trading, trading at approximately HKD 90.9 per share with turnover of HKD 300 million, extending its prior session's over-5% decline. The continued sell-off was driven by the company's H1 earnings missing market expectations, compounded by lingering concerns over the broader bispecific antibody sector.

AKESO reported H1 total revenue of RMB 1.806 billion, up 27.92% year-over-year, with commercial sales revenue rising 28.65%. However, the company posted a net loss of RMB 447 million, and while losses narrowed approximately 24% versus the prior year, revenue and gross profit fell short of consensus. Operating cash flow turned positive at RMB 290 million, but the persistent losses weighed on sentiment following a 14% rally in the two sessions prior to the earnings release, fueled by ivonescimab's positive Phase 3 biliary tract cancer trial results.

Adding to the pressure, AstraZeneca's PD-1/CTLA-4 bispecific antibody clinical failure sparked broader market skepticism toward the bispecific antibody space. AKESO Chairman Xia Yu responded that molecular structural differences across companies' bispecific antibodies are fundamental, and a single project failure should not negate the entire field — but the controversy continues to weigh on investor confidence.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)